Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 19/20 | 0.41 |
| ▸ | CDK2 | P24941 | 19/20 | 0.41 |
| ▸ | CCND1 | P24385 | 18/20 | 0.41 |
| ▸ | CDK6 | Q00534 | 18/20 | 0.41 |
| ▸ | CDK4 | P11802 | 3/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.41 |
| ▸ | CDK9 | P50750 | 2/20 | 0.41 |
| ▸ | CCND3 | P30281 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30839147 | 1.00 | CCNE1 (0.41) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL22553652 | 0.88 | CCND1 (0.40) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL22553453 | 0.88 | CCND1 (0.40) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL22553576 | 0.85 | CCND1 (0.37) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL22553575 | 0.85 | CCND1 (0.37) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL30839200 | 0.85 | CCNE1 (0.43) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL30839124 | 0.82 | CCNE1 (0.46) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL25907827 | 0.82 | CCNE1 (0.58) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL25907793 | 0.82 | CCNE1 (0.58) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL24571933 | 0.81 | CCNE1 (0.57) | CCNE1CDK2CCND1CDK6CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3956031-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | Pfizer Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| US-11203594-B2 | Anti-proliferative agents for treating PAH | PFIZER INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-11203594-B2 | Anti-proliferative agents for treating PAH | PFIZER INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-20200331909-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | PFIZER INC. (US) | 2020-10-22 | — | — | US | disclosed |
| WO-2020212865-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | PFIZER INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| US-20200331909-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | PFIZER INC. (US) | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11203594-B2 | Anti-proliferative agents for treating PAH | EDNRB, EDNRA, PAH | CCNE1 90/4885CDK2 286/4885CCND1 108/4885 |
| US-20200331909-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | EDNRB, EDNRA, PAH | CCNE1 90/4885CDK2 286/4885CCND1 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.